Cervical cancer screening in partly HPV vaccinated cohorts - A cost-effectiveness analysis

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Naber, Steffie K ^a   Matthijsse, Suzette M ^a   Rozemeijer, Kirsten ^a   Penning, Corine ^a   De Kok, Inge M C M ^a   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TESTING; INCREMENTAL COST EFFECTIVENESS RATIO; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SCREENING; SCREENING FREQUENCY; SCREENING INTERVAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS EXAMINATION; WART VIRUS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; MIDDLE AGED; THEORETICAL MODEL; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNITY, HERD; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84958576252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145548     Document Type: Article

References (54)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. Epub 1999/08/19. doi: 10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F [pii] PMID: 10451482.
2. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1):89-99. Epub 2011/11/15. [pii] doi: 10.1016/S1470-2045(11)70286-8 PMID: 22075171.
3. Future I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341: c3493. Epub 2010/07/22. PMID: 20647284; PubMed Central PMCID: PMC2907480. doi: 10.1136/bmj. c3493
4. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131(10):2349-59. Epub 2012/02/11. doi: 10.1002/ijc.27485 PMID: 22323075.
5. U.S. Food and Drug Administration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV Dec 10 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm.
6. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012; 7(1):38. Epub 2013/01/01. [pii] doi: 10.1186/1750-9378-7-38 PMID: 23273245; PubMed Central PMCID: PMC3554470.
7. van 't Schurink-van 't Klooster TM, Kemmeren JM, Vermeer-de Bondt PE, Oostvogels B, Phaff TAJ, De Melker HE, et al. Human papillomavirus vaccination catch-up campaign in 2009 for girls born in 1993 to 1996 in the Netherlands. Bilthoven: National Institute for Public Health and the Environment, 2011 Contract No.: 210012001/2011.
8. van Lier EA, Oomen PJ, Conyn-van Spaendonck MAE, Drijfhout IH, Zonnenberg-Hoff IF, De Melker HE. Immunisation coverage National Immunisation Programme in the Netherlands: Year of report 2015. Bilthoven: National Institute for Public Health and the Environment, 2015.
9. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5):565-80. Epub 2015/03/07. [pii] doi: 10.1016/S1473-3099(14)71073- 4 PMID: 25744474.
10. Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010; 46(16):2973-85. Epub 2010/07/20. doi: S0959-8049(10)00532-0 [pii] doi: 10.1016/j.ejca.2010.06.016 PMID: 20638840.
11. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer. 2012; 106(9):1571-8. Epub 2012/03/24. [pii] doi: 10.1038/bjc.2012.94 PMID: 22441643; PubMed Central PMCID: PMC3341862.
12. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst. 2008; 100(5):308-20. Epub 2008/03/04. [pii] doi: 10.1093/jnci/djn019 PMID: 18314477; PubMed Central PMCID: PMC3099548.
13. Coupe VM, Bogaards JA, Meijer CJ, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine. 2012; 30(10):1813-22. Epub 2012/01/14. doi: S0264-410X(12)00002-3 [pii] doi: 10.1016/j.vaccine.2012.01.001 PMID: 22240341.
14. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137(4):516-42. Epub 2012/03/21. doi: 137/4/516 [pii] doi: 10.1309/AJCPTGD94EVRSJCG PMID: 22431528.
15. Moyer VA, Force USPST. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156(12):880-91, W312. Epub 2012/06/20. doi: 1183214 [pii] doi: 10.7326/0003-4819-156-12-201206190-00424 PMID: 22711081.
16. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries-an update. Stockholm: 2012.
17. Herzog TJ, Wright JD. The impact of cervical cancer on quality of life-the components and means for management. Gynecol Oncol. 2007; 107(3):572-7. Epub 2007/10/30. doi: S0090-8258(07)00775-5 [pii] doi: 10.1016/j.ygyno.2007.09.019 PMID: 17963826.
18. Heinonen A, Tapper AM, Leminen A, Sintonen H, Roine RP. Health-related quality of life and perception of anxiety in women with abnormal cervical cytology referred for colposcopy: an observational study. Eur J Obstet Gynecol Reprod Biol. 2013; 169(2):387-91. Epub 2013/05/07. doi: S0301-2115 (13)00178-4 [pii] doi: 10.1016/j.ejogrb.2013.03.033 PMID: 23642971.
19. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1985; 20(1):79-93. Epub 1985/05/01. PMID: 3849380.
20. Statline Database [Internet]. 2013.
21. Hospital Diagnosis Statistics 1963-1985. Utrecht: SIG (Information Centre for Health Care), 1985.
22. Netherlands Cancer Registry. Cervical cancer incidence by one-year age groups, 2000-2010.2012.
23. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007; 29(1):19-24. Epub 2007/04/13. PMID: 17429138.
24. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int J Cancer. 2004; 110(1):94-101. Epub 2004/04/01. doi: 10.1002/ijc.20076 PMID: 15054873.
25. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One. 2008; 3(11):e3743. Epub 2008/11/18. doi: 10.1371/journal.pone.0003743 PMID: 19011683; PubMed Central PMCID: PMC2581437.
26. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989; 96 (8):889-92. Epub 1989/08/01. PMID: 2775686.
27. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001; 358(9295):1782-3. Epub 2001/12/06. [pii] doi: 10.1016/S0140-6736(01) 06809-X PMID: 11734239.
28. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010; 117(2 Suppl):S5-10.Epub 2011/03/08. doi: S0090-8258(10)00087-9 [pii] doi: 10.1016/j.ygyno.2010.01.024 PMID: 20304221.
29. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG. 2012; 119(6):699-709. Epub 2012/01/19. doi: 10.1111/j.1471-0528.2011.03228.x PMID: 22251259; PubMed Central PMCID: PMC3489039.
30. Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014; 11(1): e1001585. Epub 2014/01/24. doi: 10.1371/journal.pmed.1001585 PMEDICINE-D-13-02744 [pii]. PMID: 24453946; PubMed Central PMCID: PMC3891624.
31. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer. 2005; 115(2):268-75. Epub 2005/02/03. doi: 10.1002/ijc.20846 PMID: 15688404.
32. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13(1):78-88. Epub 2011/12/20. [pii] doi: 10.1016/S1470-2045(11)70296-0 PMID: 22177579.
33. Netherlands Cancer Registry. Stage distribution and survival of cervical cancer 2012.
34. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Rotterdam: Erasmus MC, afdeling Maatschappelijke Gezondheidszorg, 2006.
35. van Ballegooijen M. Effects and Costs of Cervical Cancer Screening. Rotterdam, the Netherlands: Erasmus University; 1998.
36. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002; 287(18):2372-81. Epub 2002/05/04. doi: joc11104 [pii]. PMID: 11988058.
37. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96(8):604-15. Epub 2004/04/22. PMID: 15100338.
38. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. Epub 2009/07/10.[pii] doi: 10.1016/S0140-6736(09)61248-4 PMID: 19586656.
39. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 Suppl 5:F123-38. Epub 2012/12/05. doi: S0264-410X(12)00951-6 [pii] doi: 10.1016/j.vaccine.2012.04.108 PMID: 23199956.
40. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1):100-10.Epub 2011/11/15. [pii] doi: 10.1016/S1470-2045 (11)70287-X PMID: 22075170.
41. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12 (10):781-9. Epub 2012/08/28. [pii] doi: 10.1016/S1473-3099(12)70187-1 PMID: 22920953.
42. www.cijfersoverkanker, Incidence, survival, and mortality of cervical cancer [Internet]. 2009.
43. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 highrisk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008; 98(3):646-51. Epub 2008/01/10.[pii] doi: 10.1038/sj.bjc.6604162 PMID: 18182990; PubMed Central PMCID: PMC2243156.
44. Accetta G, Biggeri A, Carreras G, Lippi G, Carozzi FM, Confortini M, et al. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. J Med Screen. 2010; 17(4):181-9. Epub 2011/01/25. doi: 17/4/181 [pii] doi: 10.1258/jms. 2010.010019 PMID: 21258128.
45. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356 (19):1928-43. Epub 2007/05/15. doi: 356/19/1928 [pii] doi: 10.1056/NEJMoa061760 PMID: 17494926.
46. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19):1915-27. Epub 2007/05/15. doi: 356/19/1915 [pii] doi: 10.1056/NEJMoa061741 PMID: 17494925.
47. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. Epub 2010/02/09. [pii] doi: 10.1093/jnci/djp534 PMID: 20139221.
48. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-35. Epub 2009/02/25. doi: 10.1086/597307 PMID: 19236279.
49. Brotherton JM, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013; 199(9):614-7. Epub 2013/11/05. doi: 10.5694/mja13.10272 [pii]. PMID: 24182228.
50. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14(10):958-66. Epub 2014/08/12. [pii] doi: 10.1016/S1473-3099(14)70841-2 PMID: 25107680.
51. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011; 204(3):372-6. Epub 2011/07/12. [pii] doi: 10.1093/infdis/jir285 PMID: 21742835.
52. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007; 13(1):28-41. Epub 2007/03/21. doi: 10.3201/eid1301.060438 PMID: 17370513; PubMed Central PMCID: PMC2725801.
53. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010; 28(24):4091-102. Epub 2009/11/17. doi: S0264-410X(09)01485-6 [pii] doi: 10.1016/j.vaccine.2009.09.125 PMID: 19909831.
54. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009; 19 (8):531-8. Epub 2009/04/28. doi: S1047-2797(09)00083-0 [pii] doi: 10.1016/j.annepidem.2009.03.011 PMID: 19394865; PubMed Central PMCID: PMC2880849.